(-)-Salbutamol

HCID 123600CAS 34391-04-3

Grundinformationen

Standard-SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N
Summenformel
C13H21NO3
Durchschnittliche Molmasse
239,31 g/mol
Monoisotopische Masse
239,15214353

Überblick

(R)-salbutamol is an albuterol.

Namen und Bezeichner

Bevorzugter Name
(-)-Salbutamol
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
Englischer Name
Levalbuterol
Summenformel
C13H21NO3
Molmasse
239.31

Namen und Synonyme

LevalbuterolLevosalbutamol(-)-Salbutamol34391-04-3(R)-salbutamol(-)-AlbuterolR-Salbutamol4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolEDN2NBH5SSASF-1096CHEBI:8746DTXSID80187964
Weitere Namen anzeigen
LEVALBUTEROL HCLSalbutamolr-albuterolLevalbutreol(L)-ALBUTEROLR-SALBUTAMOL HCLLEVOSALBUTEROLHCL
levosalbutamolum4-((1R)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenolAlbuterol (r)-Levalbuterol InhalationRefChem:56698Hydrochloride, LevalbuterolHydrochloride, LevosalbutamolDTXCID40110455

Datenbank-Bezeichner

CAS
34391-04-3
PubChem CID
123600
DTXSID
DTXSID80187964
ChEMBL
CHEMBL1002
ChEBI
CHEBI:8746
UNII
EDN2NBH5SS
EC Number
608-983-3
Nikkaji
J428.072E

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,3
Polarare Oberfläche (TPSA)
72,7 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
5
Schwere Atome
17

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists
Collision Cross Section153.47 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Siedepunkt
433.5 · 433.5±40.0 °C(Predicted)
Dichte
1.152 · 1.152±0.06 g/cm3(Predicted)
pka
9.99 · 9.99±0.31(Predicted)
InChI
InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
InChIKey
NDAUXUAQIAJITI-PLAQIDKDNA-N
SMILES
C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|

Sicherheit und Regulatorisches

Toxikologische Informationen

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1 Eintrag

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

Sicherheitsdaten

risk_code
22
hazard_code
Xn
safety_code
36

Chemie und Industrie

Pharmakologische Informationen

Protein Bindingplasma protein binding is relatively low.
PharmacodynamicsIt acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
Mechanism of Action · 1 Eintrag

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Biological Half-Life3.3 - 4 hours
Metabolism/Metabolites · 2 Einträge

Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6 Einträge

EDN2NBH5SS

LEVALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.

LEVALBUTEROL

Verwendung und Herstellung

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
Anwendungen · 2 Einträge

BeschreibungLevalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.

Verwenden(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.

Anbieter36 Anbieter

Suzhou ARTK Medchem Co., Ltd.+86-18168183658 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
广东云星生物技术有限公司0751-18902340975/189023400307 18902340307 · [email protected]
InvivoChem中国13549236410 · [email protected]

Zugehörige Reaktionen

3

Verknüpfte Notizen

Wird geladen…